Key Takeaways

  • VLP Peanut delivered positive Phase I/IIa safety and biomarker data, including basophil sensitivity reductions of 376%-489% at the highest dose.
  • Grassmuno, the company's grass pollen product, secured Germany's first TAV-pathway approval and launched commercially in January 2026.
  • The company raised £55 million via Warrant exercise in October 2025, clearing its Shareholder Loan Facility and drawing £40 million from a new Hayfin facility.
  • A trading update for the year to 30 June 2026 showed Revenue accelerating to £59.9 million, up 9%, with year-end cash of £24.2 million.
  • Helge Weiner-Trapness was appointed Executive Chairman in July 2026, succeeding Peter Jensen OBE, with Manuel Llobet remaining chief executive.

Allergy Therapeutics (LSE:AGY), the Worthing-based maker of injectable allergy immunotherapies, has had an eventful year. Since December 2025 the AIM-listed group has reported clinical progress in both flagship allergen programmes, secured its first grass pollen product approval under Germany's dedicated regulatory pathway, and overhauled a Balance Sheet dependent on shareholder Debt . Shares have swung between roughly 5p and over 12p over the past year, as the market weighs scientific progress against the dilution and execution risk that has come with it.

What Happened

The peanut allergy candidate, VLP Peanut, delivered two positive readouts from its Phase I/IIa PROTECT trial. In December 2025 the company said the trial had met its primary safety endpoint after 48 participants completed dosing, with a 2,000-fold dose escalation achieved without safety concerns. In March 2026 it followed with positive biomarker data, including reductions in basophil sensitivity of 376% for peanut and 489% for the Ara h2 peanut protein at the highest dose, plus a dose-dependent rise in protective IgG antibodies. Chief executive Manuel Llobet said the results "demonstrate clinical proof of concept" for VLP Peanut.

On the grass side, Phase III data from the G306 trial of Grass MATA MPL was published in the Journal Allergy in February 2025, showing a 20.3% reduction in combined symptom and medication score versus placebo. That underpinned a German Marketing authorisation, branded Grassmuno, granted in December 2025 under the country's Therapieallergene-Verordnung (TAV) framework — the first subcutaneous grass pollen immunotherapy approved that way. Grassmuno launched commercially in mid-January 2026, and a paediatric Phase III trial, G308, entered its second recruitment year in October 2025.

Alongside the science, the company restructured its finances. In October 2025 it raised £55 million by exercising 1.375 billion warrants at 4p each, clearing its shareholder loan facility in full, then drew £40 million from a new secured facility with Hayfin, with a further £50 million unsecured facility available. In July 2026, Helge Weiner-Trapness, a former HSBC vice-chairman of global banking, was appointed Executive Chairman, succeeding Peter Jensen OBE; Llobet remains chief executive.

Why It Matters

The clinical data matter because they extend Allergy Therapeutics' evidence base beyond grass pollen into peanut allergy, a market with no approved injectable immunotherapy. Positive biomarker and safety signals from PROTECT give management a case for progressing VLP Peanut into a Phase IIb trial with food-challenge endpoints, the step that would test real-world efficacy rather than surrogate markers alone.

Grassmuno's TAV approval is the first tangible regulatory win from years of Investment in Grass MATA MPL, converting a pipeline asset into a product sold into Germany's insurance-reimbursed allergy market. The refinancing addresses a genuine balance-sheet overhang: shareholder debt had ballooned to over £53 million by June 2025, and its removal cuts interest costs and eases the going-concern uncertainty that had shadowed recent annual reports.

Latest Financial and Operational Performance

Full-year results for the year ended 30 June 2025 showed revenue broadly flat at £55.0 million (FY2024: £55.2 million), a gross Margin of 53.2%, an operating loss of £28.2 million and a net loss of £40.1 million, with cash of £12.8 million.

Interim results to 31 December 2025 showed revenue up 7% to £36.3 million, though gross margin slipped to 59% from 61% on higher volumes and cost Inflation . The pre-R&D operating result swung to a £2.5 million loss (H1 2025: £1.9 million profit) as Grassmuno launch costs were absorbed, and the net loss widened to £19.9 million (H1 2025: £11.9 million).

A trading update for the year to 30 June 2026 showed revenue accelerating to £59.9 million, up 9% (around 5% at constant currency), with second-half growth of 12% outpacing 7% in the first half. Germany grew over 4% despite the TAV transition, while Spain delivered 12% growth. Cash rose to £24.2 million by year-end, and management guided to "double digit revenue growth" for the year to June 2027.

Key Numbers

  • FY2025 revenue: £55.0m (FY2024: £55.2m); net loss £40.1m; cash £12.8m
  • H1 FY2026 (to 31 Dec 2025): revenue £36.3m (+7%); net loss £19.9m; cash £10.1m
  • FY2026 trading update: revenue £59.9m, up 9%; year-end cash £24.2m
  • £55m raised via warrant exercise (Oct 2025); £40m Hayfin secured facility drawn; £50m unsecured facility available
  • G306 Grass Phase III: 20.3% reduction in combined symptom/medication score vs placebo (p=0.0005)
  • PROTECT peanut trial: 48 patients dosed; basophil sensitivity reduced 376%–489% at highest dose
  • Shares around 5.9p (28 July 2026); 52-week range 5.00p–12.10p; market cap roughly £374m

Growth Opportunities

The clearest near-term driver is Grassmuno's rollout through its first full German pre-season in autumn 2026, in a market sized at roughly $1 billion by 2030. Beyond Germany, management wants to extend the MATA MPL platform and TAV-style regulatory approach to other allergens and geographies. In peanut allergy, a positive Phase IIb readout for VLP Peanut would open a second major indication with no direct injectable competitor. The company is also evaluating a dual listing on the Hong Kong Stock Exchange, broadening its investor base and supporting a push into Asian markets, though this remains conditional on regulatory approval.

Risks Investors Should Know

Allergy Therapeutics (LSE:AGY) remains loss-making, and the warrant exercise that repaired its balance sheet also diluted shareholders, with shares in issue now above 6 billion. The new Hayfin facility carries a meaningful interest cost, and further funding needs cannot be ruled out. VLP Peanut has only reported safety and biomarker data; Phase IIb efficacy results are not guaranteed. Revenue remains concentrated in a handful of European markets, and Grassmuno's uptake depends on prescriber and payer behaviour under the still-evolving TAV framework.

What to Watch Next

Watch for the initiation of a VLP Peanut Phase IIb trial, further G308 paediatric data through 2026, and Grassmuno's first full autumn selling season under TAV. Updates on the proposed Hong Kong listing and audited results for the year to 30 June 2026, expected around December 2026, will show whether revenue growth is translating into a narrower loss.

Outlook

Allergy Therapeutics enters the second half of 2026 stronger than a year ago, with a repaired balance sheet, a newly approved German grass product and encouraging early peanut data. The pieces are falling into place; the remaining question is whether execution and further clean clinical readouts can turn a long loss-making profile into sustainable profit.